Remote Regulatory Assessments Will Continue Post Pandemic, Says US FDA
Executive Summary
The US FDA has issued guidance on how it will continue to use remote technology to assess agency regulated facilities, a practice that became popular during COVID-19 travel restrictions.
You may also be interested in...
Global Medtech Guidance Tracker: July 2022
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-five documents have been posted on the tracker since its last update.
How The US FDA’s Inspectional Approach Is Shifting For The Post-Pandemic Era
Agency hints of a “hybrid” future of in-person inspections supplemented by alternative tools like remote interactive evaluations.
US FDA Explains How It Is Embracing Remote Assessments Post-Pandemic
Agency provides additional details on plans for various remote methods of assessing Rx and OTC drug manufacturing facilities that became popular when investigators were prevented by COVID-19 travel restrictions from visiting sites in person.